Seth M. Lederman

This study compares the attenuation of TNX-801, a recombinant chimeric Horsepox virus, to VACV-based vaccines in cell lines and mice, showing TNX-801 is significantly more attenuated.

This paper shows that a CXCR4 partial agonist enhances immunotherapy in gastric cancer by targeting PMN-MDSCs and granulopoiesis.

This study evaluates the immunogenicity and efficacy of TNX-1800, a poxvirus vaccine expressing SARS-CoV-2 spike protein, in nonhuman primates challenged with SARS-CoV-2.

This study evaluates the immunogenicity and tolerability of the SARS-CoV-2 vaccine TNX-1800 in hamsters and rabbits, finding it well-tolerated with undetectable viral load after 28 days.